Forte Biosciences (FBRX) Stock Overview
Operates as a clinical-stage biopharmaceutical company in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
FBRX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Forte Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$13.66 |
| 52 Week High | US$28.68 |
| 52 Week Low | US$4.11 |
| Beta | 2.97 |
| 1 Month Change | 20.67% |
| 3 Month Change | 145.68% |
| 1 Year Change | 3.09% |
| 3 Year Change | -64.29% |
| 5 Year Change | -96.33% |
| Change since IPO | -96.75% |
Recent News & Updates
Recent updates
We Think Forte Biosciences (NASDAQ:FBRX) Needs To Drive Business Growth Carefully
Apr 19
We're A Little Worried About Forte Biosciences' (NASDAQ:FBRX) Cash Burn Rate
Jul 17Is Forte Biosciences (NASDAQ:FBRX) In A Good Position To Deliver On Growth Plans?
Mar 14Large Forte Biosciences shareholder scolds company board of directors
Aug 24We're Hopeful That Forte Biosciences (NASDAQ:FBRX) Will Use Its Cash Wisely
Aug 17Forte Biosciences: Lots Of Clinical Risk Ahead And A Questionable Business Plan
Aug 16Forte Biosciences large shareholders make demands for company's future
Jul 07We Think Forte Biosciences (NASDAQ:FBRX) Needs To Drive Business Growth Carefully
Dec 23Are Insiders Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Stock?
Mar 13Do Institutions Own Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?
Jan 19
Who Has Been Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?
Nov 25Shareholder Returns
| FBRX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 5.6% | 3.9% | 1.8% |
| 1Y | 3.1% | -6.8% | 13.7% |
Return vs Industry: FBRX exceeded the US Biotechs industry which returned -6.8% over the past year.
Return vs Market: FBRX underperformed the US Market which returned 13.7% over the past year.
Price Volatility
| FBRX volatility | |
|---|---|
| FBRX Average Weekly Movement | 21.2% |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 17.2% |
| 10% least volatile stocks in US Market | 3.7% |
Stable Share Price: FBRX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: FBRX's weekly volatility (21%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 14 | Paul A. Wagner | www.fortebiorx.com |
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company’s lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo. Forte Biosciences, Inc. is headquartered in Dallas, Texas.
Forte Biosciences, Inc. Fundamentals Summary
| FBRX fundamental statistics | |
|---|---|
| Market cap | US$166.84m |
| Earnings (TTM) | -US$43.71m |
| Revenue (TTM) | n/a |
Is FBRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FBRX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$43.71m |
| Earnings | -US$43.71m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.58 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did FBRX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/07 14:49 |
| End of Day Share Price | 2025/07/03 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Forte Biosciences, Inc. is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kalpit Patel | B. Riley Securities, Inc. |
| Kumaraguru Raja | Brookline Capital Markets |
| Keay Nakae | Chardan Capital Markets, LLC |